AN2 Therapeutics closed at $4.25 on Nov 4, up 1.67%, 32.3% below its 52-week closing high. Volume of 132.0K shares was 0.43× its 20-day average (below normal).
Split-adjusted performance: -16.2% over one month, -8.6% over six months, +269.6% over one year.
Short interest was 2.9M shares at the Oct 15 settlement, up 15.9% from the prior report (10.0% of float, 7.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ANTXAN2 Therapeutics | $4.25 | +1.67% | −8.6% | — | — | — | $160.4M | |
| ZNTLZentalis Pharmaceuticals | $1.76 | −1.12% | −57.9% | — | — | — | $166.6M | Compare |
| INOInovio Pharmaceuticals | $1.62 | −2.41% | +30.6% | — | — | — | $167.5M | Compare |
| SIONSionna Therapeutics | $3.73 | +2.19% | −91.4% | — | — | — | $168.6M | Compare |
| PEPGPepGen | $2.45 | −0.41% | +32.8% | — | — | — | $169.7M | Compare |
| ORMPOramed Pharmaceuticals | $4.13 | +3.25% | +5.4% | — | — | 1.0 | $171.8M | Compare |
| RNAAtrium Therapeutics | $8.68 | −0.46% | −33.7% | −21.9% | −672.0% | — | $148.5M | Compare |
| MGNXMacroGenics | $2.31 | −0.86% | −23.3% | +378.0% | 59.4% | — | $147.1M | Compare |
| CUECue Biopharma | $19.84 | −4.89% | −41.6% | +166.7% | −1943.2% | — | $144.1M | Compare |
No recent articles focused on AN2 Therapeutics. 1 articles mention it in passing.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
